Responsible lobbying

As a leading pharmaceutical company, Novartis endeavors to play an active role in public policy debates affecting our business. We believe it is our responsibility to share our perspective, scientific knowledge and technical expertise by providing fact-based information to policymakers and regulatory authorities.

We strive to engage in constructive partnership with government and other stakeholders to increase access to the best medicines and to health information globally, while preserving incentives for research and innovation through competitive pricing.

We believe it is in the interest of companies striving for a leadership role in corporate citizenship to campaign for policies and regulations which favor ethical business conduct.

Much of this work is done through trade associations, which can be a powerful vehicle for raising standards across industry and an effective forum for the exchange of best practice.

In our lobbying and advocacy activities - as in all other areas of our business - we are governed by the Novartis Code of Conduct and we strive for integrity, openness, transparency and consistency in our business activities.

Download the Novartis Code of Conduct
(62 KB)

 

In 2009, Novartis registered on the European Commission’s Register of Interest Representatives.

This voluntary-based self-regulation system, established by the European Commission, is aimed at increasing transparency. It is supported by a register for interest representatives and is linked to a code of conduct. As a registrant, Novartis is committed to:

• publishing an estimate of the costs associated with direct lobbying of the EU institutions incurred by in-house lobbyists
• subscribing to the Commission’s Code of Conduct or a comparable professional code

Visit the European Commission’s Register of Interest Representatives website